Source: Annual Congress 2006 - Bronchiolo-alveolar carcinoma
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
M. Wislez (Paris, France). Predicting activity of EGFR (epidermal growth factor receptor) inhibitors in diffuse bronchiolo-alveolar carcinoma or so-called pneumonic adenocarcinoma. Annual Congress 2006 - Bronchiolo-alveolar carcinoma

Member's Comments

No comment yet.

Related content which might interest you: A novel biologic classification of non-small cell lung cancer Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology Year: 2005 Influence of histological subtypes of bronchioloalveolar carcinoma on prognosis and treatment Source: Annual Congress 2006 - Prognostic factors in lung cancer Year: 2006 Tumor-derived tumor necrosis factor-α promotes Lewis lung cancer-induced malignant pleural effusions in mice Source: Annual Congress 2006 - Molecular pathology and genetics of lung cancer Year: 2006 Should there be a specific management for large cell neuroendocrine carcinoma? Source: Annual Congress 2005 - Neuroendocrine tumours of the lung Year: 2005 TNFα as a prognostic factor in surgically treated non-small cell lung carcinomas Source: Annual Congress 2005 - Management of lung cancer: clinical problems Year: 2005 A non-small cell lung cancer modelling by endogenous κ-ras manipulation Source: Annual Congress 2005 - Pathophysiology of lung cancer progression: impact in diagnosis and early detection Year: 2005 Trail receptors as prognostic factors in non-small cell lung cancer Source: Annual Congress 2007 - Biology in thoracic oncology Year: 2007 Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation Source: Eur Respir J 2011; 37: 624-631 Year: 2011 Lung cancer Source: Respipedia Article Year: 2018 How to treat brain metastasis in patients with non-small cell lung carcinoma (NSCLC) and EGFR mutations Source: International Congress 2015 – How to treat brain metastases Year: 2015 Composite anatomical–clinical–molecular prognostic model in nonsmall cell lung cancer Source: Eur Respir J 2011; 37: 136-142 Year: 2011 Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy Source: Eur Respir J 2012; 39: 1437-1442 Year: 2012 Age and stage at presentation in lung cancer Source: Annual Congress 2005 - Management of lung cancer: clinical problems Year: 2005 A prospective phase II study of gefitinib for chemo-naïve patients with advanced non-small cell lung cancer with epidermal growth factor receptor gene mutations Source: Annual Congress 2006 - Lung cancer treatment Year: 2006 The biology of lung cancer Source: ISSN=1025-448x, ISBN=1-904097-18-9, page=61 Year: 2001 COX-2 as prognostic factor in lung cancer: systematic review of the literature with meta-analysis Source: Annual Congress 2005 - Prognostic factors in lung cancer Year: 2005 Prognostic factors in pathological stage IB nonsmall cell lung cancer greater than 3 cm Source: Eur Respir J 2010; 36: 1355-1361 Year: 2010 The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival Source: Eur Respir J 2007; 30: Suppl. 51, 280s Year: 2007 The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer Source: Eur Respir Rev 2010 19: 186-196 Year: 2010 Carbonic anhydrase 9 expression (CA9e) profile combined with growth patterns (GPs) in non-small cell lung cancer (NSCLC) identifies a group of patients with an extremely poor prognosis Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology Year: 2005